Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights

PARIS, FRANCE, 14 OCTOBER 2025 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that its Board of Directors has been informed of the conclusion of a new agreement¹ between Highrock (controlled by Anne Beaufour), Beech Tree (controlled by Henri Beaufour) and MR BMH (controlled by Henri Beaufour) relating to the existing concerted action between members of the Beaufour family, controlling shareholders of Ipsen.

The agreement provides for a consultation process between Highrock and Beech Tree ahead of meetings of the Company’s Board of Directors and General Assembly of Shareholders, with the aim of reaching a common position on strategic decisions.

The agreement also provides that, in the event of the resignation or non-renewal of a director nominated on the proposal of Highrock or Beech Tree, the company that proposed them may put forward a candidate with the necessary skills in accordance to the criteria set out in the agreement.

The agreement further provides for a commitment by the parties to ensure that, by the General Assembly of Shareholders called to approve the financial statements for the fiscal year ending 31 December 2025, the Compensation Committee and the Nomination Committee each have a majority of independent directors, including their chair, and an equal number of directors proposed by Highrock and Beech Tree.

The agreement is valid until 31 December 2028 and will be automatically renewed for successive two-year periods unless terminated by one of the parties.

This agreement does not modify the shareholding of the entities related to Ms. Anne Beaufour and Mr. Henri Beaufour, which remain unchanged.

The Board of Directors has acknowledged the renewed support of its principal shareholders.

¹ It is recalled that the shareholders’ agreement concluded on 19 December 2019 between Highrock, Beech Tree, MR BMH, as well as MR Schwabe, FinHestia, Finvestan and Finveska (controlled by the Schwabe family) remains unchanged. It provides for a voting pool mechanism covering 28.22% of Ipsen’s capital and 36.14% of its voting rights, for which voting at the General Assembly of Shareholders is determined by a 75% majority of the pooled shares.

About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts
Investors
Henry Wheeler henry.wheeler@ipsen.com +33 7766471149
Khalid Deojee khalid.deojee@ipsen.com +33 666019526

Media (Global)
Sally Bain sally.bain@ipsen.com  +1 8573200517

Media (France)
Anne Liontas anne.liontas.ext@ipsen.com  +33 0767347296

Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

Attachment

• Ipsen Media Statement_Shareholders Representation_14102025